** Medical device maker Solventum's SOLV.N shares rise ~2.6% to $77.82
** Argus Research upgrades Solventum to "buy" from "hold"
** Brokerage says SOLV transformed into faster-growing and higher-margin business model
** Argus raises SOLV's 2026 adjusted EPS estimate to $5.98 from $5.95
** Four of 13 brokerages rate stock "buy" or higher, eight "hold" and one "sell"; their median PT is $85 - LSEG data
** Including session's moves, stock up ~17.3% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.